A randomised phase II trial of ¹⁷⁷Lu-PSMA-617 (Lu-PSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results

TheraP (ANZUP 1603)

Michael Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony Joshua, Jeffrey Goh, David Pattison, Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn Francis, Craig Gedye, Natalie Rutherford, Alison Zhang, Margaret McJannett, Martin Stockler, John Violet, Scott Williams, Andrew Martin, Ian Davis

TheraP is a partnership between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) in collaboration with the NHMRC CTC and the Australasian Radiopharmaceutical Trials Network (ARTnet) with support from the Australian Nuclear Science and Technology Organisation (ANSTO) and Endocyte Inc., a Novartis company

Clinicaltrials.gov NCT03392428





#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.



Metastatic Castration Resistant Prostate Cancer (mCRPC): History and Current State of the Art

- mCRPC: a lethal disease and novel treatments are needed to improve outcomes¹
 - Life prolonging therapies include docetaxel¹, abiraterone², enzalutamide³, sipuleucel-T⁴ and ²²³Ra⁵
 - Docetaxel-resistant mCRPC: cabazitaxel 个OS compared to mitoxantrone⁷ and 2nd line novel anti-androgen⁸

prostate specific membrane antigen (PSMA): protein on prostate cancer cell surface

prostate cancer cell

2

¹⁷⁷Lu-PSMA-617 (Lu-PSMA): radiolabelled small molecule binds to PSMA

- Delivers therapeutic β-radiation to mCRPC
- Encouraging efficacy and safety in non-randomised trials of mCRPC⁹⁻¹¹
- Phase II study: PSA \geq 50% in 64% of men with low toxicity¹²⁻¹³

TheraP: first randomised trial comparing Lu-PSMA to an active therapy (cabazitaxel) in men with mCRPC progressing after docetaxel

¹Gillessen S *Eur Urol* 2020;77(4) ²Tannock IF *NEJM* 2004;351(15) ³de Bono JS *NEJM* 2011;364(21) ⁴Scher HI *NEJM* 2012;367(13) ⁵Kantoff PW *NEJM* 2010;353(5) ⁶Parker C et *NEJM* 2013;369(3) ⁷de Bono JS *Lancet* 2010;376(9747) ⁸de Wit R *NEJM* 2019;381(26)



#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

PRESENTED BY: Michael Hofman, MBBS @DrMHofman

⁹Kratochwil C *Eur J Nucl Med Mol Imaging* 2015;42(6) ¹⁰Rahbar K *J Nucl Med* 2017;58(1) ¹¹Heck MM *Eur Urol* 2019;75(6) ¹²Hofman MS *Lancet Oncol* 2018;19(8) ¹³Violet J *J Nucl Med* 2019;Nov 15 epub



Aim: to determine the activity and safety of Lu-PSMA vs cabazitaxel

R

KEY ELIGIBILITY

- mCRPC post docetaxel suitable for cabazitaxel
- Progressive disease with rising PSA and PSA ≥ 20 ng/mL
- Adequate renal, haematologic and liver function
- ECOG performance status 0-2

⁶⁸Ga-PSMA + ¹⁸F-FDG PET/CT

- PSMA SUVmax > 20 at any site
- Measurable sites SUVmax > 10
- No FDG positive/PSMA negative sites of disease
- Centrally reviewed

¹⁷⁷Lu-PSMA-617

8.5 GBq IV q6 weekly Ψ 0.5GBq each cycle Up to 6 cycles

200 men 1:1 randomisation 11 sites in Australia

Stratified by:

- Disease burden (>20 sites vs ≤ 20 sites)
- Prior enzalutamide or abiraterone
- Study site

CABAZITAXEL

20mg/m² IV q3 weekly, Up to 10 cycles

80% power to detect a true absolute difference of 20% in the PSA response rate (from 40% to 60%), with a 2-sided type 1 error of 5% and allowance of 3% for missing data.

SPECT/CT @ 24 hours

suspend Rx if exceptional

response; recommence upon progression




#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

PRESENTED BY: Michael Hofman, MBBS @DrMHofman

Protocol paper: Hofman MS BJUI Int 2019;124(S1)

3



Intention-to-treat (ITT) analysis + sensitivity analysis for per-protocol analysis

ANZUP




4

#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

Patient selection: PSMA and FDG PET/CT







5

#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

TheraP Endpoints



• Primary Endpoint

• PSA response, defined by PSA reduction of ≥ 50% from baseline (PSA50-RR) (PCWG3)

Secondary Endpoints

- PSA progression-free survival (PFS) (PCWG3)
- Adverse events (CTCAE v4.03)
- Objective tumour response (RECIST v1.1)
- Pain response (McGill-Melzack Present pain intensity (PPI) scale and analgesic score)
- Radiographic PFS (PCWG3 criteria for bone lesions and RECIST 1.1 for soft tissue lesions)
- Pain PFS
- Overall PFS (time to PSA progression, pain progression, radiographic progression or death)
- Health related quality of life (EORTC Core Quality of Life Questionnaire C30 [QLQ-C30], PDF)
- Overall survival

Not reported in this analysis; further follow-up pending



#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

PRESENTED BY: Michael Hofman, MBBS @DrMHofman

PCWG3: Prostate Cancer Working Group Criteria version 3 CTCAE: NCI Common Terminology Criteria for Adverse Events PDF: Patient disease and Treatment Assessment Form

Results: patient characteristics

	Cabazitaxel (N=101)	Lu-PSMA (n=99)
Age (Years): Median (IQR)	72 (67 to 77)	72 (67 to 77)
Prior enzalutamide or abiraterone	91 91	
Disease burden (> 20 sites)	79	77
ECOG performance status 0 1 2 unknown	44 52 4 1	42 53 4
PSA: Median (IQR)	110 (64 to 245)	94 (44 to 219)
ALP: Median (IQR)	130 (79 to 187)	111 (83 to 199)
Gleason Score at diagnosis ≤ 7 ≥ 8 unknown	35 50 16	25 53 21

• Updated dataset¹ with cut-off 31 MAR 2020

Median follow-up of 13.3 months (IQR: 9.5 to 17.7) months



7

#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.


PRESENTED BY: Michael Hofman, MBBS @DrMHofman

¹Updated compared to ASCO abstract first analysis cut-off 31 DEC 2019



Cancer Trials Group Limited

Primary endpoint: PSA ≥ 50% response (PSA50-RR)



Lu-PSMA: 29% absolute (95% CI 16%-42%; p<0.0001) greater PSA50-RR compared to cabazitaxel


For sensitivity analysis per-protocol, the difference was 23% (95% CI 9%-37%; p=0.0016)



#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

Secondary endpoint: PSA PFS (preliminary)





* Primary analysis at 170 events (as per SAP)

p<0.0027 is required to trigger rejection of null hypothesis prior to planned primary analysis at 170 events (as per SAP) There have been 71 deaths in total.



#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

Safety: Selected Adverse Events by Worst Grade

	()
ANZ Cancer Trials Grou	

Term	Cabazitaxel (N=85)		Lu-PSMA (N=98)	
	G1-2	G3-4	G1-2	G3-4
	%	%	%	%
Neutropenia (+/- fever)	5	13	6	4
Thrombocytopaenia	4	0	17	11
Dry mouth	21	0	59	0
Diarrhea	52	5	18	1
Dry eye	4	0	30	0
Dysgeusia	27	0	12	0
Neuropathy (motor or sensory)	26	1	10	0
Fatigue	72	4	70	5
Nausea	34	0	39	1
Anaemia	12	8	18	8
Vomiting	12	2	12	1
TOTAL (all AEs)	40	54	53	35

Discontinuations for toxicity occurred in 1/98 (1%) Lu-PSMA vs. 3/85 (4%) Cabazitaxel-treated. There were no Lu-PSMA related deaths; 5 G5 AEs for cabazitaxel and 11 G5 AEs for Lu-PSMA.



10

#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

Strengths and Limitations



Strengths

- First randomised trial of Lu-PSMA
- Active and clinically relevant control arm
- Use of ¹⁸F-FDG and ⁶⁸Ga-PSMA PET/CT to select patients
- Large difference in primary endpoint

Limitations

- Await further follow-up for results of other key secondary endpoints including:
 - Radiologic PFS (next planned analysis after 170 events)
 - Quality of Life
 - PFS / OS
- Not blinded
- Withdrawal before treatment
 - PSA50-RR intention to treat analysis
 - PSA50-RR per protocol analysis

Lu-PSMA Cabazitaxel 1/99 (1%) vs 16/101 (16%) 65/99 (66%) vs 37/101 (37%), difference 29%, p < 0.0001 65/98 (66%) vs 37/ 85 (44%), difference 23%, p = 0.0016



Clinical interpretation

- Novel class of radiopharmaceutical with high activity and relatively low toxicity, consistent with results of prior single-center phase II data¹
- May represent favourable treatment option compared to Cabazitaxel in a selected population with high PSMA-expression (72%)
- Improvement in overall survival not yet defined
 - Results of upcoming phase 3 VISION trial (NCT03511664) pending
- Warrants study in earlier phases of prostate cancer and/or in combination with other therapies



12

#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.



In men with progressive disease following docetaxel, Lu-PSMA was more active (higher PSA50-RR) than Cabazitaxel, with relatively fewer G3-4 AEs, and PSA-PFS favouring Lu-PSMA

Lu-PSMA represents a potential new class of effective therapy for men with metastatic castration-resistant prostate cancer



13

#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

Acknowledgements

We thank:

- Patients and support network
- Principal and co-investigators
- Study coordinators
- Nurses
- Radiopharmacists/chemists
- Nuclear medicine technologists
- Clinical research associates
- Data managers

Industry support:

- PSMA-617 supply and financial support: Endocyte Inc., a Novartis company
- Lutetium-177 no carrier added supplied from Australian Nuclear Science and Technology Organisation (ANSTO)

Funding:

- Prostate Cancer Foundation of Australia with thanks to community generosity of
 - Movember
 - It's a Bloke Thing Foundation
 - Can4Cancer
- Cancer Australia (ANZUP infrastructure support)
- M Hofman: Peter MacCallum Foundation

2 BLOKI

THING

MOVEMB

I Davis: NHMRC Practitioner Fellowship



Study designed and conducted by the ANZUP in collaboration with:

- NHMRC Clinical Trials Centre at the University of Sydney
- Australasian Radiopharmaceutical Trials Network (ARTnet)







Prostate Cancer




#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.

PRESENTED BY: Michael Hofman, MBBS @DrMHofman

@ANZUP #TheraP

www.anzup.org.au/therap

#TheraP Study Team





#ASCO20 #TheraP Slides are the property of the author, permission required for reuse.